Sign inJoin waitlistJoin the waitlist

Rom Leidner

Associate Program Director · Swedish Medical Center

Credentials: · · · · ·

History

Swedish Medical Center
Present
Providence Health & Services - Oregon
Present

Case Western Reserve University/University Hospitals Cleveland Medical Center
1999–2001
Virginia Mason Medical Center On line Request
1996–1999
Hadassah Ein Kerem Medical Center
1993–1996
Internal Medicine
Maimonides Medical Center
1990–1993
University of Colorado at Boulder
1986–1990

Research

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Nature Communications · 2018 · 786 citations
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Journal for ImmunoTherapy of Cancer · 2019 · 571 citations
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer
New England Journal of Medicine · 2022 · First of 14 authors · 442 citations

Bryan Bell
19 papers
MC
Marka Crittenden
11 papers
WU
Walter Urba
10 papers
Carlo Bifulco
9 papers
Brendan Curti
6 papers
Marcus Couey
5 papers · 5 as a resident
Robert Ferris
5 papers
Zipei Feng
5 papers
Allen Cheng
4 papers
Amitabh Chak
4 papers
Balazs Halmos
4 papers
HX
Hong Xiao
4 papers

Clinical trials

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
Principal investigator · Recruiting · Phase 1
Providence Health & Services
2025–2030
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Principal investigator · Active not recruiting · Phase 1
Providence Health & Services
2023–2028
Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Principal investigator · Active not recruiting · Phase 1
Providence Health & Services
2022–2027
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer
Principal investigator · Active not recruiting · Phase 1, Phase 2
Providence Health & Services
2018–2026